Implantation FailureNCT07669623
Effects of Different Acupuncture Techniques on the Success Rate in Patients With Recurrent Implantation Failure
A study testing acupuncture group 1 and acupuncture group 2 in people with Implantation Failure, run by Cui Hong Zheng at 1 site in China.
Trial summary
To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of different acupuncture methods on the success rate in patients with recurrent implantation failure Read more about this study
- Who is it for?
- Ages Up to 39 years, women only
- Conditions the study is for
- Implantation Failure
- What is being tested?
- acupuncture group 1 and acupuncture group 2
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 312 participants
- Where
- 1 siteChina
- Study dates
- 1 Sep 2026to 30 Jun 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 39 years
- Women only
- No healthy volunteers
- Child, Adult
Who may be able to join
- Meets the criteria for RIF diagnosis (≥ 3 instances of unsuccessful transfer of high-quality embryos).
- Age: < 40 years.
- Planning for a cycle involving the transfer of frozen-thawed embryos (FET).
- Possession of a transplantable frozen blastocyst (≥3BB).
- Endometrial thickness >7 mm within the period of endometrial transformation.
Who cannot join
- Individuals planning to undergo preimplantation genetic diagnosis (PGD).
- Recipients of egg donations.
- Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms).
- Patients with known embryo-related factors leading to implantation failure.
- Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on).
- Those with significant abnormalities in immunity or coagulation.
Show all 13Show fewer
- Individuals with other endocrine disorders, such as thyroid disorders, hyperprolactinemia, insulin resistance, diabetes, and adrenal disorders, whose hormone levels have not been well-controlled over the past 3 months.
- Individuals with untreated hydrosalpinx;
- Individuals with a Body Mass Index (BMI) below 18 and above 25 kg/ m2.
- Men with severe abnormalities in semen quality.
- Individuals with a history of needle phobia.
- Individuals who have previously participated in this study or received acupuncture treatment within the past three months;
- Any other conditions deemed unsuitable for participation by the researchers.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Tongji Hospital,Tongji medical college,HUST
Wuhan, Hubei, 430030
Cuihong Zheng, professor, 86-27-83663275, chzheng@tjh.tjmu.edu.cn
About this study
To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of different acupuncture methods on the success rate in patients with recurrent implantation failure
- Conditions
- Implantation Failure
- Being tested
- Placebo Group, acupuncture group 1, acupuncture group 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo GroupDevice
nonpenetrating placebo needles
acupuncture group 1Device
indwelling intradermal needles
acupuncture group 2Device
combining fire needle and regular acupuncture
| Study group | Role | What they receive |
|---|---|---|
| placebo acupuncture group | Placebo comparator | nonpenetrating placebo needles Receives: Device: Placebo Group |
| acupuncture group 1 | Experimental | indwelling intradermal needles Receives: Device: acupuncture group 1 |
| acupuncture group 2 | Experimental | combining fire needle and regular acupuncture Receives: Device: acupuncture group 2 |
What is being measured
The primary outcome is the main question the study is designed to answer.
clinical pregnancy
defined as ultrasonographic detection of an intrauterine gestational sac following embryo transfer
Measured: 2 years
Secondary outcomes (2)
β-hCG-positive pregnancy
defined as serum β-hCG concentration >10 mIU/mL on day 14 post-transfer
Measured: 2 years
live birth
defined as the delivery of 1 or more living infants at greater than 20 weeks' gestation or birth weight of at least 400 g
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2026
- Study start1 Sep 2026 (estimated)
- Primary completion30 Jun 2028 (estimated)
- Study completion30 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Implantation FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 312 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cui Hong Zheng
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Cui Hong Zheng, Huazhong University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07669623
- Sponsor's protocol ID
- TJ-IRB202605092
- Status last verified
- Aug 2026
- First submitted
- 20 Jun 2026
- Last updated
- 26 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Different Acupuncture Techniques on the Success Rate in Patients With Recurrent Implantation Failure
- ClinicalTrials.gov ID
- NCT07669623
- Acronym / sponsor ID
- TJ-IRB202605092
- Conditions
- Implantation Failure
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 312 participants (estimated)
- Lead sponsor
- Cui Hong ZhengUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 30 Jun 2028 (estimated)
- Study completion
- 30 Jun 2029 (estimated)
- First posted
- 25 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of different acupuncture methods on the success rate in patients with recurrent implantation failure
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| placebo acupuncture group | Placebo comparator | Device: Placebo Groupnonpenetrating placebo needles |
| acupuncture group 1 | Experimental | Device: acupuncture group 1indwelling intradermal needles |
| acupuncture group 2 | Experimental | Device: acupuncture group 2combining fire needle and regular acupuncture |
Who may qualify
- Ages
- Up to 39 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (5 listed)
- Meets the criteria for RIF diagnosis (≥ 3 instances of unsuccessful transfer of high-quality embryos).
- Age: < 40 years.
- Planning for a cycle involving the transfer of frozen-thawed embryos (FET).
- Possession of a transplantable frozen blastocyst (≥3BB).
- Endometrial thickness >7 mm within the period of endometrial transformation.
Key exclusion criteria (13 listed)
- Individuals planning to undergo preimplantation genetic diagnosis (PGD).
- Recipients of egg donations.
- Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms).
- Patients with known embryo-related factors leading to implantation failure.
- Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo Groupnonpenetrating placebo needles | Device | placebo acupuncture group |
| acupuncture group 1indwelling intradermal needles | Device | acupuncture group 1 |
| acupuncture group 2combining fire needle and regular acupuncture | Device | acupuncture group 2 |
Primary outcome
clinical pregnancy
Time frame: 2 years
defined as ultrasonographic detection of an intrauterine gestational sac following embryo transfer
2 secondary outcomes
β-hCG-positive pregnancy
Time frame: 2 years
live birth
Time frame: 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Implantation Failure
Not yet recruiting
Safety Assessment of Placing a Single Dental Implant Without Antibiotic Prophylaxis in Simple Cases: A Pilot Study
Tooth Loss and Rehabillitation, Dental Implant Failure
RecruitingObservational study
dPmax for Predicting Right Ventricular Failure After Left Ventricular Assist Device Implantation
Ventricular Dysfunction, Right
Recruiting
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
End Stage Renal Disease
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Active, not recruitingObservational study
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Aortic Valve Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing acupuncture group 1 and acupuncture group 2 in people with Implantation Failure, run by Cui Hong Zheng at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pu Zhou (+8602783662379, tongjihlunli@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
clinical pregnancy (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.